Phoria are an English art rock band based in Brighton, consisting of Trewin Howard, Ed Sanderson, Jeb Hardwick, James "Cheese" Cheeseman, and Seryn Burden. Phoria released their debut EP, Yourself Still, in 2010, followed by Bloodworks (2013) and Display (2014). The records earned the band international critical and popular acclaim. The bands first full-length album, Volition, was released on 3 June 2016. Their second album, Caught a Black Rabbit, came out on 13 November 2020. Biography
Phoria members Trewin, Jeb and Ed went to primary as school together in Salisbury, where they learned cello, classical guitar, and violin respectively. As friends, they spent their youth making music together before leaving for university in 2005. Jeb and Ed both attended the University of Southampton. Ed continued to study music, specialising in violin and piano. Jeb studied for a sociology degree, though spent much of his time experimenting with music and visual arts. Trewin attended the Dartington College of Arts in Devon. He  had initially enrolled on as fine arts course but was soon drawn back to music. Having completed their studies, Trewin, Ed, and Jeb returned to Salisbury and took full time jobs. Jebs included a brief spell as an insurance agent. Ed, with a passion for acting, took large but unfulfilling parts in a series of niche-market films. It was not long before the three of them realised that their future lay elsewhere, and moved to Brighton to start their musical careers.
Second line treatment for psoriasis (slows down the rapid division of skin cells)
Systemic mastocytosis
Chronic myelogenous leukemia (largely replaced by imatinib, but still in use for its cost-effectiveness)

Side effects
Reported side effects are: neurological reactions (e.g., headache, dizziness, drowsiness, disorientation, hallucinations, and convulsions), nausea, vomiting, diarrhea, constipation, mucositis, anorexia, stomatitis, bone marrow toxicity (dose-limiting toxicity; may take 7–21 days to recover after the drug has been discontinued), megaloblastic anemia, thrombocytopenia, bleeding, hemorrhage, gastrointestinal ulceration and perforation, immunosuppression, leukopenia, alopecia (hair loss), skin rashes (e.g., maculopapular rash), erythema, pruritus, vesication or irritation of the skin and mucous membranes, pulmonary edema, abnormal liver enzymes, creatinine and blood urea nitrogen.Due to its negative effect on the bone marrow, regular monitoring of the full blood count is vital, as well as early response to possible infections. In addition, renal function, uric acid and electrolytes, as well as liver enzymes, are commonly checked. Moreover, because of this, its use in people with leukopenia, thrombocytopenia or severe anemia is contraindicated.Hydroxycarbamide has been used primarily for the treatment of myeloproliferative diseases, which has an inherent risk of transforming to acute myeloid leukemia. There has been a longstanding concern that hydroxycarbamide itself carries a leukemia risk, but large studies have shown that the risk is either absent or very small. Nevertheless, it has been a barrier for its wider use in patients with sickle-cell disease.